ARROWHEAD PHARMACEUTICALS, INC. Defined Contribution Plan, Cost
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Defined Contribution Plan, Cost of $3.90 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2025-11-25
- ARROWHEAD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2025 was $3.90M, a 14.71% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2024 was $3.40M, a 54.55% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2023 was $2.20M, a 29.41% increase from fiscal 2022.
- ARROWHEAD PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2022 was $1.70M, a 30.77% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2025-09-30 | $3.90M 10-K · filed 2025-11-25 | |
| 2024-09-30 | $3.40M 10-K · filed 2025-11-25 | |
| 2023-09-30 | $2.20M 10-K · filed 2025-11-25 | |
| 2022-09-30 | $1.70M 10-K · filed 2024-11-26 | |
| 2021-09-30 | $1.30M 10-K · filed 2023-11-29 | |
| 2020-09-30 | $900.00K 10-K · filed 2022-11-28 | $863.08K 10-K · filed 2020-11-23 |
| 2019-09-30 | $500.00K 10-K · filed 2021-11-22 | $545.70K 10-K · filed 2019-11-25 |
| 2018-09-30 | $451.62K 10-K · filed 2020-11-23 | |
| 2017-09-30 | $426.47K 10-K · filed 2019-11-25 | |
| 2016-09-30 | $476.83K 10-K · filed 2018-12-11 | |
| 2015-09-30 | $407.60K 10-K · filed 2017-12-12 | |
| 2014-09-30 | $264.19K 10-K · filed 2016-12-14 | $264.19M 10-K · filed 2014-11-25 |
| 2013-09-30 | $191.95K 10-K · filed 2015-12-14 | $191.95M 10-K · filed 2014-11-25 |
| 2012-09-30 | $162.50M 10-K · filed 2014-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |